ST香雪及其子公司涉及诉讼金额累计超九千万元

Company Dynamics - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (ST Xiangxue) is facing multiple challenges, with over 92.26 million yuan in litigation amounts disclosed in the past year, accounting for 8.78% of the company's latest audited net assets [2] - The company has been involved in significant legal disputes, including a contract dispute amounting to 20.92 million yuan and a financial loan dispute totaling 44.96 million yuan [2] - Established in 1986, ST Xiangxue has developed a full industry chain from traditional Chinese medicine cultivation to production and distribution, with core products including medicinal syrups and granules [2] Financial Performance - Since 2016, ST Xiangxue's net profit has declined significantly, with a drop of over 60% in 2016 to 66.02 million yuan, and subsequent years maintaining net profits between 60 million and 70 million yuan [3] - The company reported a loss of 677 million yuan in 2021, followed by losses of 530 million yuan, 389 million yuan, and 859 million yuan in 2022, 2023, and 2024 respectively [3] - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [3] Restructuring Efforts - The pre-restructuring process was approved by the Guangzhou Intermediate People's Court, initially set for three months but has faced multiple extensions, now extended to January 11, 2026 [3][4] - Despite ongoing restructuring efforts, the company projected a significant loss for 2025, estimating a net loss between 635 million yuan and 934 million yuan [4] - Contributing factors to the losses include intensified market competition, liquidity issues, high financial costs, and asset impairment provisions totaling approximately 130 million yuan [4][5]